Beijing SL Pharmaceutical Co., Ltd.

Beijing SL Pharmaceutical Co., Ltd. saw a notable increase in its stock today, contrasting with a decline in the broader market. However, the company has struggled over the past year and three years, with significant declines in performance metrics and ongoing challenges in sales and inventory management.

Beijing SL Pharmaceutical Co., Ltd. saw a notable stock increase today, contrasting with the broader market's modest rise. However, the company has struggled over the past year and decade, facing profitability challenges and reporting a significant net loss, while working to improve its market position.

Beijing SL Pharmaceutical Co., Ltd. has recently experienced a change in evaluation, reflecting a shift in its technical indicators. The company faces challenges, including a low Return on Capital Employed and declining net sales and operating profit over the past five years, alongside negative results for four consecutive quarters.

Beijing SL Pharmaceutical Co., Ltd. saw a notable increase in stock performance on March 27, 2026, reaching an intraday high. Despite recent gains, the company faces long-term challenges, including a year-to-date decline. It operates in the Pharmaceuticals & Biotechnology sector and has a market capitalization of CNY 5,417 million.